Beau-Larvor; Charlotte

Patent Applications and Registrations

Patent applications and USPTO patent grants for Beau-Larvor; Charlotte.The latest application filed is for "antibody-drug-conjugate and its use for the treatment of cancer".

Company Profile

10.11.16

Beau-Larvor; Charlotte - Jonzier Epagny FR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
IGF-1R antibody and its use as addressing vehicle for the treatment of cancer Grant 11,365,259 - Goetsch , et al. June 21, 2	2022-06-21
Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20220105195 - RILATT; Ian ; et al.	2022-04-07
Antibody-drug-conjugate and its use for the treatment of cancer Grant 11,219,693 - Rilatt , et al. January 11, 2	2022-01-11
Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20210038738 - RILATT; Ian ; et al.	2021-02-11
Composition for the treatment of IGF-1R expressing cancer Grant 10,858,423 - Jouhanneaud , et al. December 8, 2	2020-12-08
Igf-1r Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20200270352 - RILATT; Ian ; et al.	2020-08-27
IGF-1R antibody-drug-conjugate and its use for the treatment of cancer Grant 10,633,448 - Rilatt , et al.	2020-04-28
Igf-1r Antibody And Its Use As Addressing Vehicle For The Treatment Of Cancer App 20190330353 - GOETSCH; Liliane ; et al.	2019-10-31
Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20190269788 - RILATT; Ian ; et al.	2019-09-05
Composition For The Treatment Of Igf-1r Expressing Cancer App 20190202901 - JOUHANNEAUD; Alexandra ; et al.	2019-07-04
Antibody-drug-conjugate and its use for the treatment of cancer Grant 10,314,921 - Rilatt , et al.	2019-06-11
IGF-1R antibody and its use as addressing vehicle for the treatment of cancer Grant 10,202,458 - Goetsch , et al. Feb	2019-02-12
Antigen binding protein and its use as addressing product for the treatment of cancer Grant 10,161,930 - Beau-Larvor , et al. Dec	2018-12-25
Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20180228915 - RILATT; Ian ; et al.	2018-08-16
Igf-1r Antibody And Its Use As Addressing Vehicle For The Treatment Of Cancer App 20170267766 - GOETSCH; Liliane ; et al.	2017-09-21
Antigen binding protein and its use as addressing product for the treatment of cancer Grant 9,689,862 - Beau-Larvor , et al. June 27, 2	2017-06-27
Antigen binding proteins Grant 9,624,308 - Beau-Larvor , et al. April 18, 2	2017-04-18
Igf-1r Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20170043031 - RILATT; Ian ; et al.	2017-02-16
Antibody-drug-conjugate And Its Use For The Treatment Of Cancer App 20170043032 - RILATT; Ian ; et al.	2017-02-16
Novel Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer App 20160131639 - Beau-Larvor; Charlotte ; et al.	2016-05-12
Axl Antibody-drug Conjugate And Its Use For The Treatment Of Cancer App 20160106861 - BEAU-LARVOR; Charlotte ; et al.	2016-04-21
Novel Antigen Binding Proteins And Their Use As Addressing Product For The Treatment Of Cancer App 20160046725 - BEAU-LARVOR; Charlotte ; et al.	2016-02-18
Antigen binding protein and its use as addressing product for the treatment of cancer Grant 9,173,962 - Beau-Larvor , et al. November 3, 2	2015-11-03
Novel Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer App 20150037340 - Beau-Larvor; Charlotte ; et al.	2015-02-05
Novel Antigen Binding Protein And Its Use As Addressing Product For The Treatment Of Cancer App 20140141023 - BEAU-LARVOR; Charlotte ; et al.	2014-05-22

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.